Abstract
We compare the design, mechanism of action, and clinical efficacy of two recently licensed paradigm shifting vaccines. Zostavax is the first vaccine licensed to prevent disease in patients already infected with a pathogen, and is contrasted with Gardasil and Cervarix, the first vaccines designed and licensed specifically to prevent cancers.
MeSH terms
-
Alphapapillomavirus / genetics
-
Alphapapillomavirus / immunology*
-
Animals
-
Clinical Trials as Topic
-
Female
-
Herpes Zoster / immunology
-
Herpes Zoster / prevention & control*
-
Herpes Zoster / virology
-
Herpesvirus 3, Human / genetics
-
Herpesvirus 3, Human / immunology*
-
Humans
-
Papillomavirus Vaccines / genetics
-
Papillomavirus Vaccines / immunology*
-
Uterine Cervical Neoplasms / immunology
-
Uterine Cervical Neoplasms / prevention & control*
-
Uterine Cervical Neoplasms / virology